Trastuzumab

ATC CODE

  • L01XC03

INDICATIONS AND NEMLC RECOMMENDATIONS

INDICATIONS AND NEMLC RECOMMENDATIONS 1

INDICATION

  • Adjuvant treatment for early stage HER-2 positive breast cancer, 6 month regimen.

NEMLC RECOMMENDATION

  • Approved
    Regimen: administered 3 weekly for a period of 6 months.

REVIEW INDICATORS

  • New evidence

DATE RATIFIED

  • 5 December 2019 (previously reviewed: 29 June 2017)

INDICATIONS AND NEMLC RECOMMENDATIONS 2

INDICATION

  • Adjuvant treatment for early stage HER-2 positive breast cancer, 12 month regimen

NEMLC RECOMMENDATION

  • Not Approved
    Decision re-evaluated – see above – 6 month regimen recommended.

REVIEW INDICATORS

  • n/a

DATE RATIFIED

  • Previous recommendation: 29 June 2017